Moderna Stock Surges As It Swings For Pfizer, GSK With New RSV Vaccine Results | Canada News Media
Connect with us

Health

Moderna Stock Surges As It Swings For Pfizer, GSK With New RSV Vaccine Results

Published

 on

Moderna (MRNA) stock surged early Wednesday after the company said its experimental RSV vaccine proved nearly 84% effective against respiratory symptoms in older adults.

The company tested its vaccine in people age 60 and older. It was 83.7% effective against mild respiratory syncytial virus, or RSV. The virus causes cold-like symptoms. It can be deadly in infants who have virtually nonexistent immune systems and older adults who have weakened immunity.

The results are competitive with Pfizer (PFE) and GSK (GSK), both of which are approaching Food and Drug Administration review dates for their RSV vaccines in May. Johnson & Johnson (JNJ) and Bavarian Nordic trail with potential vaccines.

Moderna is planning to file for approval of its RSV vaccine in the first half of this year. Needham analyst Joseph Stringer expects the FDA to approve the shot before year’s end.

“We think Moderna’s profile is competitive and has the potential to capture a meaningful share of the multi-billion dollar RSV market,” he said in a note to clients.

Moderna Stock: A Battle Brewing In RSV

In premarket action on the stock market today, Moderna stock surged 6.3% near 202.70.

Moderna Chief Executive Stephane Bancel says the results further prove the capabilities of the company’s platform in messenger RNA, or mRNA. In the body, messenger RNA carries the genetic instructions for making proteins. Vaccines take advantage of this process, telling the body to make specific proteins in order to prompt an immune response.

“Today’s results represent an important step forward in preventing lower respiratory disease due to RSV in adults 60 years of age and older,”Bancel said in a written statement issued late Tuesday. “These data are encouraging and represent the second demonstration of positive Phase 3 (study) results from our mRNA infectious disease platform.”

Moderna tested its RSV vaccine in 37,000 adults age 60 or older in 22 countries, including the U.S. The company reported an interim analysis, examining the number of participants to develop two or more symptoms of RSV. Of the 64 people to develop symptoms, 55 received the placebo. Nine were vaccine recipients.

Another measure looked at participants to develop three or more symptoms of RSV. Moderna said there were 20 people in the study to hit that mark, including 17 placebo recipients and three vaccinated people. That put the effectiveness at 82.4% against so-called severe RSV.

An independent team of data monitors reviewed Moderna’s test results and said there have been no safety concerns.

The results help Moderna stock continue trending higher. Shares have turned around this month and have a strong Relative Strength Rating of 90 out of a best-possible 99, according to IBD Digital. This puts Moderna stock in the leading 10% of all stocks in terms of 12-month performance.

Comparing RSV Vaccines

Now, Moderna plans to submit the data to a peer-reviewed publication and present more data at a future infectious diseases conference.

By comparison, GSK has said its RSV vaccine was almost 83% effective overall and more than 94% protective against severe RSV in adults age 60 and older with underlying health problems. Pfizer’s shot was close to 67% protective overall and about 86% effective against severe disease.

“Based on high level comparison with vaccine effectiveness from RSV vaccines from competitors Pfizer, GSK and J&J, we see these results as likely approvable and plausibly competitive with those agents,” SVB Securities analyst Mani Foroohar said in a note. He noted the results are still early and comparing the various competitors’ studies “should consequently be taken with a grain of salt.”

Trailing, Bavarian Nordic plans to have its Phase 3 RSV vaccine results in the middle of the year. J&J is also in final-phase testing with results possible in the second half of 2024, Needham’s Stringer said.

Foroohar, the SVB analyst, expects Moderna to ask for a speedy review of its RSV vaccine.

This would allow “approval in time to give Moderna a more fulsome opportunity to participate in the 2023 contracting season,” he said. Foroohar boosted his price target on Moderna stock to 111 from 102, but kept his market perform rating.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Bizarre Sunlight Loophole Melts Belly Fat Fast!

Published

 on

Product Name: Bizarre Sunlight Loophole Melts Belly Fat Fast!

Click here to get Bizarre Sunlight Loophole Melts Belly Fat Fast! at discounted price while it’s still available…

 

All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Bizarre Sunlight Loophole Melts Belly Fat Fast! is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.

(more…)

Continue Reading

Trending

Exit mobile version